Nalaganje...

ET-19 A PHASE 1 STUDY EVALUATING ABT-414 WITH TEMOZOLOMIDE (TMZ) OR CONCURRENT RADIOTHERAPY (RT) AND TMZ IN GLIOBLASTOMA (GBM)

BACKGROUND: Standard therapies have little effect on the poor survival rates of GBM. Abnormal epidermal growth factor receptor (EGFR) expression and signaling are common in GBM. ABT-414 is a unique antibody-drug conjugate, with a toxic payload (MMAF) targeted to active EGFR or mutant EGFRvIII, that...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Gan, Hui K., Fichtel, Lisa, Lassman, Andrew B., Merrell, Ryan, van den Bent, Martin, Kumthekar, Priya, Scott, Andrew M., Pedersen, Michelle, Gomez, Erica, Fischer, JuDee, Ames, William, Xiong, Hao, Dudley, Matt, Munasinghe, Wijith, Roberts-Rapp, Lisa, Ansell, Peter, Holen, Kyle, Reardon, David A.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2014
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218114/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou255.19
Oznake: Označite
Brez oznak, prvi označite!